The occurrence and frequency of anaphylactic reactions in the use of infliximab – a prospective study in a large single center

Introduction: Antagonizing Tumor Necrosis Factor Alpha (TNFα) has become an effective strategy in treatment of moderate and severe Crohn's disease (CD) and ulcerative colitis (UC). Infliximab (Remicade, Schering Plough), a recombinant IgG1 monoclonal antibody, was the first TNF-α-antibody approved for the treatment of CD and UC, respectively. Since anaphylactic reactions occur frequently with infliximab, we analyzed prospectively the frequency of these reactions in a normal clinical single center. Methods: Frequency and character of infliximab induced anaphylactic reactions in treatment of severe and refractory…